The latest news, announcements and press releases from Persist AI.
SAN FRANCISCO, Feb. 18, 2026 /PRNewswire/ -- CyanoCapture, the innovator in cyanobacteriabased oral drug delivery, and Persist AI, the leader in AI-driven robotic pharmaceutical formulation, today announced a strategic collaboration to jointly build a next-generation GMP manufacturing facility in the San Francisco Bay Area. The facility, expected to be operational by Q4 2026, will be the first of its kind to combine cyanobacteria culture and processing with robotic automation for clinical-scale production of novel oral protein and peptide therapeutics.
The two companies intend to leverage their complementary expertise and technology to bring a novel long acting injectable and drug product manufacturing platform to market.
SACRAMENTO, Calif., Aug. 12, 2024 /PRNewswire/ -- Persist AI and Nivagen have announced a collaboration to co-develop a next-generation manufacturing process for long-acting injectable (LAI) drugs, using Persist's AI-based formulation technology and Nivagen's manufacturing capabilities. The collaboration aims to simplify and accelerate the development and approval of LAI drugs, which can provide sustained and controlled release of drugs over weeks or months, improving patient adherence and outcomes.
This is the News section of the company profile page for Persist AI on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
